Age related changes in fractional elimination pathways for drugs: Assessing the impact of variable ontogeny on metabolic drug-drug interactions

Journal of Clinical Pharmacology

Volumn 53, Issue 8, 2013, Pages 857-865

  Salem, Farzaneh ^a   Johnson, Trevor N ^b   Barter, Zoe E ^b   Leeder, J Steven ^c,d,e   Rostami hodjegan, Amin ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Drug drug interaction; Ontogeny; Pediatric

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; KETOCONAZOLE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; INFANT; NEWBORN; ONTOGENY; PRESCHOOL CHILD; SCHOOL CHILD;

DRUG-DRUG INTERACTION; ONTOGENY; PEDIATRIC;

AGING; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84885032015     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.100     Document Type: Article

References (25)

1. Crocker JF, Renton KW, LeVatte TL, McLellan DH. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Pediatr Nephrol. 1994;8(4):408-411. (Pubitemid 24228627)
2. Salem F, Rostami-Hodjegan A, Johnson TN. Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol. 2013;53(5):559- 566.
3. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349 (12):1157-1167. (Pubitemid 37122329)
4. Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm. 1973;1(6):553-567.
5. Rostami-Hodjegan A, Tucker GT. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Tech. 2004;1(4):441-448.
6. Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol. 2001;51(5):451-460. (Pubitemid 32852983)
7. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931-956. (Pubitemid 44299829)
8. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67-76.
9. Allegaert K, Vanhole C, Vermeersch S, Rayyan M, Verbesselt R, de Hoon J. Both postnatal and postmenstrual age contribute to the interindividual variability in tramadol glucuronidation in neonates. Early Hum Dev. 2008;84(5):325-330. (Pubitemid 351626893)
10. Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphanO- andN-demethylation in the first year of life. Clin Pharmacol Ther. 2007;81(4):510-516. (Pubitemid 46452306)
11. Mukherjee A, Dombi T, Wittke B, Lalonde R. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther. 2009;85(1):56-63.
12. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research, 4th edition. Oxford: Wiley-Blackwell; 2001.
13. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4):169-175. (Pubitemid 350194376)
14. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965-974. (Pubitemid 38263972)
15. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem. 1998;251(3):893-898. (Pubitemid 28108986)
16. Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci. 1997;61(26):2567-2574. (Pubitemid 28035581)
17. Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E. Human hepatic CYP2B6 developmental expression: The impact of age and genotype. Biochem Pharmacol. 2009;78(2):184-190.
18. Leong R, Vieira ML, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91(5):926-931.
19. Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006;45(7):683-704. (Pubitemid 43990570)
20. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59(6):691-704. (Pubitemid 40835503)
21. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2011;21(3):291-301.
22. Johnson TN, Tucker GT, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther. 2008;83(5):670-671. (Pubitemid 351556011)
23. Rostami-Hodjegan A. Physiologically-based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: A marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50-61.
24. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the Investigation of Drug Interactions. 2012 [Accessed Nov 27, 2012]; Available from: http://www.ema.europa.eu/docs/en.guideline/2012/./ WC500129606.pdf.
25. DIA Dispatch. Today's Headline: Application of PBPK Modeling to Pediatric Drugs Cautiously Favoured. 2012 [Accessed Nov 27, 2012]; Available from: http://www.diahome.org/productfiles/11275/disptch-1484.pdf.